Clin Gastroenterol Hepatol. 2026 Feb 17:S1542-3565(26)00066-2. doi: 10.1016/j.cgh.2026.01.037. Online ahead of print.
ABSTRACT
The ability to precisely determine future risk of advanced neoplasia (AN; high-grade dysplasia and/or colorectal cancer [CRC]) in patients with ulcerative colitis (UC) and low-grade dysplasia (LGD) is a major unmet need. Given the uncertainty in existing prognostic data, current guidelines advise incorporating expert opinion into management decisions, which can be challenging and imprecise.1 In addition to supporting clinician decision-making, having quantitative estimates of cancer risk also increases patients’ ability to make informed shared decisions on surgery vs continued intensive surveillance following a LGD diagnosis.2.
PMID:41713829 | DOI:10.1016/j.cgh.2026.01.037